Literature DB >> 22866098

Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: Qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions.

Yasunori Ariyoshi1, Masashi Shimahara, Yoshihiro Kimura, Yuichi Ito, Takeshi Shimahara, Shin-Ichi Miyatake, Shinji Kawabata.   

Abstract

The present study aimed to demonstrate the features of fluorine-18-labeled boronophenylalanine positron emission tomography ((18)F-BPA-PET) to reveal oral cancer, as well as normal structures in the oral and maxillofacial regions. We analyzed (18)F-BPA-PET findings from 8 patients with histologically confirmed recurrent and/or advanced oral cancer scheduled for boron neutron capture therapy. The capacity of (18)F-BPA-PET to delineate tumor and normal structures was assessed qualitatively and quantitatively. Tumors were easily identified as high uptake areas in all cases. Although the eyes, which were depicted as a low uptake area, and tongue musculature were readily identified, major vessels were not noted in any of the cases. Areas corresponding to the surface of the dorsum tongue to middle pharynx were expressed as high uptake areas in all of the cases. Quantitatively, tumors were expressed as the highest uptake area in 6 of the 8 cases, while the dorsum tongue had the highest uptake area in the remaining 2 cases. (18)F-BPA-PET is useful in demonstrating the presence of a tumor. Thus, it is crucial to note the presence of a high uptake area corresponding to the dorsum area of the tongue when diagnosing a tumor using this technique.

Entities:  

Year:  2011        PMID: 22866098      PMCID: PMC3410502          DOI: 10.3892/ol.2011.265

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

Review 1.  Boron neutron capture therapy of cancer: current status and future prospects.

Authors:  Rolf F Barth; Jeffrey A Coderre; M Graça H Vicente; Thomas E Blue
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

2.  Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Yoshinaga Kajimoto; Atsushi Aoki; Kunio Yokoyama; Makoto Yamada; Toshihiko Kuroiwa; Motomu Tsuji; Yoshio Imahori; Mitsunori Kirihata; Yoshinori Sakurai; Shin-Ichiro Masunaga; Kenji Nagata; Akira Maruhashi; Koji Ono
Journal:  J Neurosurg       Date:  2005-12       Impact factor: 5.115

3.  Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound.

Authors:  Y Mishima; C Honda; M Ichihashi; H Obara; J Hiratsuka; H Fukuda; H Karashima; T Kobayashi; K Kanda; K Yoshino
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

4.  18F-FDG PET in squamous cell carcinoma of the oral cavity and oropharynx: a study on inter- and intraobserver agreement.

Authors:  Christiaan A Krabbe; Jan Pruim; Asbjørn M Scholtens; Jan L N Roodenburg; Adrienne H Brouwers; T T Ha Phan; Ali Agool; Pieter U Dijkstra
Journal:  J Oral Maxillofac Surg       Date:  2010-01       Impact factor: 1.895

5.  Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Authors:  Minoru Miyashita; Shin-Ichi Miyatake; Yoshio Imahori; Kunio Yokoyama; Shinji Kawabata; Yoshinaga Kajimoto; Masa-Aki Shibata; Yoshinori Otsuki; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

6.  The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.

Authors:  Hung-Jen Hsieh; Sheng-Hsiang Lin; Ko-Han Lin; Chien-Ying Lee; Cheng-Pei Chang; Shyh-Jen Wang
Journal:  Ann Nucl Med       Date:  2008-08-01       Impact factor: 2.668

7.  A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease.

Authors:  Paul M Busse; Otto K Harling; Matthew R Palmer; W S Kiger; Jody Kaplan; Irving Kaplan; Cynthia F Chuang; J Tim Goorley; Kent J Riley; Thomas H Newton; Gustavo A Santa Cruz; Xing-Qi Lu; Robert G Zamenhof
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

8.  The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma.

Authors:  George W Kabalka; Trent L Nichols; Gary T Smith; Laurence F Miller; Mohammad K Khan; Paul M Busse
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

9.  Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.

Authors:  Yasunori Ariyoshi; Shin-Ichi Miyatake; Yoshihiro Kimura; Takeshi Shimahara; Shinji Kawabata; Kenji Nagata; Minoru Suzuki; Akira Maruhashi; Koji Ono; Masashi Shimahara
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

10.  Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.

Authors:  K Ono; S I Masunaga; Y Kinashi; M Takagaki; M Akaboshi; T Kobayashi; K Akuta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-15       Impact factor: 7.038

View more
  4 in total

1.  FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model.

Authors:  Kohei Hanaoka; Tadashi Watabe; Sadahiro Naka; Yasukazu Kanai; Hayato Ikeda; Genki Horitsugi; Hiroki Kato; Kayako Isohashi; Eku Shimosegawa; Jun Hatazawa
Journal:  EJNMMI Res       Date:  2014-12-20       Impact factor: 3.138

2.  Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection.

Authors:  Takahiro Morita; Hiroaki Kurihara; Kenta Hiroi; Natsuki Honda; Hiroshi Igaki; Jun Hatazawa; Yasuaki Arai; Jun Itami
Journal:  Radiat Oncol       Date:  2018-01-11       Impact factor: 3.481

3.  Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-18F-fluoro-phenylalanine (FBPA) PET study.

Authors:  Kayako Isohashi; Eku Shimosegawa; Sadahiro Naka; Yasukazu Kanai; Genki Horitsugi; Ikuko Mochida; Keiko Matsunaga; Tadashi Watabe; Hiroki Kato; Mitsuaki Tatsumi; Jun Hatazawa
Journal:  EJNMMI Res       Date:  2016-10-18       Impact factor: 3.138

4.  Reliable radiosynthesis of 4-[10B]borono-2-[18F]fluoro-L-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis.

Authors:  Kiichi Ishiwata; Ryoichi Ebinuma; Chuichi Watanabe; Kunpei Hayashi; Jun Toyohara
Journal:  Ann Nucl Med       Date:  2018-06-05       Impact factor: 2.668

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.